Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
May 24, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
May 10, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...
Axim-Sapphire_Logo_-04 (1).png
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
April 27, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye...
Featured Image for Olympic Ophthalmics, Inc.
Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Device, Expanded Patent Portfolio, and Further Clinical Studies
March 30, 2022 09:00 ET | Olympic Ophthalmics
ISSAQUAH, Wash., March 30, 2022 (GLOBE NEWSWIRE) -- Olympic Ophthalmics announced today that the U.S. Food and Drug Administration (FDA) has granted its 510(K) request for its second-generation...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
March 08, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
March 07, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...
Global Dry Eye Syndrome Market
Worldwide Dry Eye Syndrome Industry to 2027 - Featuring Akorn, Allergan and Nicox Among Others
March 03, 2022 07:53 ET | Research and Markets
Dublin, March 03, 2022 (GLOBE NEWSWIRE) -- The "Dry Eye Syndrome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
February 15, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab...
Sohi Eye Care Announces Grand Opening of hEYEdrate Spa in Raleigh, NC
February 10, 2022 14:02 ET | Sohi Eye Care
RALEIGH, N.C., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Whether the condition is acute or chronic, dry eye syndrome can negatively impact a person's eye health and overall quality of life. That's why the...
IMED Dryeye Rescue PR post 798x530 31 Jan 2022 final
I-Med Pharma USA Partners With DryEye Rescue to Distribute Its Innovative Dry Eye Product Portfolio in the United States
February 03, 2022 11:00 ET | I-MED Pharma
MONTREAL, Feb. 03, 2022 (GLOBE NEWSWIRE) -- With the recent launch of its line of dry eye diagnostics, management, and treatment solutions into the United States, I-MED Pharma USA has partnered with...